Abstract
Belatacept, a selective T-cell costimulation blocker, was introduced as a promising change from the nephrotoxic and metabolic side effects of calcineurin (CNI) based maintenance immunosuppression. Seven-year follow up of the belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study) trial showed superior patient and graft survival along with higher mean estimated glomerular filtration rate with the use of belatacept as compared to cyclosporine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
